This is a preprint.
Evaluating the association of APOE genotype and cognitive resilience in SuperAgers
- PMID: 39830268
- PMCID: PMC11741496
- DOI: 10.1101/2025.01.07.25320117
Evaluating the association of APOE genotype and cognitive resilience in SuperAgers
Abstract
Introduction: "SuperAgers" are oldest-old adults (ages 80+) whose memory performance more closely resembles middle-aged adults. The present study examined APOE allele frequency in non-Hispanic Black (NHB) and non-Hispanic White (NHW) SuperAgers compared to controls and Alzheimer's disease dementia cases.
Methods: In 18,080 participants from eight cohorts, harmonized clinical diagnostics and memory, executive function, and language domain scores were used to identify SuperAgers, cases, and controls across age-defined bins.
Results: NHW SuperAgers had significantly lower frequency of APOE-ε4 alleles and higher frequency of APOE-ε2 alleles compared to all cases and controls, including oldest-old controls. Similar patterns were found in a small yet substantial sample of NHB SuperAgers; however, not all comparisons with controls reached significance.
Discussion: We demonstrated strong evidence that APOE allele frequency relates to SuperAger status. Further research is needed with a larger sample of NHB SuperAgers to determine if mechanisms conferring resilience differ across race groups.
Keywords: APOE genotype; Alzheimer’s disease; SuperAgers; cognitive aging; cognitive resilience.
Figures

Similar articles
-
Can we detect cognitive "super-agers" in Parkinson's disease? Cognitive, neuropsychiatric and motor outcomes in the first 10 years of Parkinson's disease.Parkinsonism Relat Disord. 2025 Apr;133:107345. doi: 10.1016/j.parkreldis.2025.107345. Epub 2025 Feb 21. Parkinsonism Relat Disord. 2025. PMID: 40015166
-
Time Course and Severity of Cognitive Changes as a Function of Aβ Positivity and APOE Genotype in Alzheimer Disease.Neurology. 2025 Jul 22;105(2):e213853. doi: 10.1212/WNL.0000000000213853. Epub 2025 Jun 27. Neurology. 2025. PMID: 40577676
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2. Cochrane Database Syst Rev. 2017. PMID: 28328043 Free PMC article.
-
¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Cochrane Database Syst Rev. 2015 Jan 28;1(1):CD010632. doi: 10.1002/14651858.CD010632.pub2. Cochrane Database Syst Rev. 2015. PMID: 25629415 Free PMC article.
References
Publication types
Grants and funding
- UH2 NS100599/NS/NINDS NIH HHS/United States
- U01 AG079850/AG/NIA NIH HHS/United States
- P30 AG066515/AG/NIA NIH HHS/United States
- U01 AG068057/AG/NIA NIH HHS/United States
- R01 AG021155/AG/NIA NIH HHS/United States
- P30 AG066462/AG/NIA NIH HHS/United States
- P30 AG072972/AG/NIA NIH HHS/United States
- R01 AG056405/AG/NIA NIH HHS/United States
- K01 AG073584/AG/NIA NIH HHS/United States
- P20 AG068082/AG/NIA NIH HHS/United States
- P30 AG072975/AG/NIA NIH HHS/United States
- P30 AG066444/AG/NIA NIH HHS/United States
- R01 AG037639/AG/NIA NIH HHS/United States
- UH3 NS100599/NS/NINDS NIH HHS/United States
- P30 AG066507/AG/NIA NIH HHS/United States
- P30 AG072946/AG/NIA NIH HHS/United States
- P30 AG066518/AG/NIA NIH HHS/United States
- R01 AG067482/AG/NIA NIH HHS/United States
- U01 NS100599/NS/NINDS NIH HHS/United States
- P30 AG066511/AG/NIA NIH HHS/United States
- P30 AG086404/AG/NIA NIH HHS/United States
- U24 AG072122/AG/NIA NIH HHS/United States
- P30 AG066512/AG/NIA NIH HHS/United States
- P30 AG062421/AG/NIA NIH HHS/United States
- U01 AG024904/AG/NIA NIH HHS/United States
- RF1 AG054074/AG/NIA NIH HHS/United States
- P30 AG066508/AG/NIA NIH HHS/United States
- P01 AG003991/AG/NIA NIH HHS/United States
- U24 AG056270/AG/NIA NIH HHS/United States
- P30 AG072978/AG/NIA NIH HHS/United States
- P01 AG026276/AG/NIA NIH HHS/United States
- R01 AG017917/AG/NIA NIH HHS/United States
- P30 AG062429/AG/NIA NIH HHS/United States
- P30 AG066519/AG/NIA NIH HHS/United States
- R01 AG028786/AG/NIA NIH HHS/United States
- U24 AG074855/AG/NIA NIH HHS/United States
- R01 AG027161/AG/NIA NIH HHS/United States
- R01 AG054047/AG/NIA NIH HHS/United States
- P30 AG072973/AG/NIA NIH HHS/United States
- P30 AG062422/AG/NIA NIH HHS/United States
- R01 AG079280/AG/NIA NIH HHS/United States
- P30 AG086401/AG/NIA NIH HHS/United States
- P30 AG010161/AG/NIA NIH HHS/United States
- P30 AG066530/AG/NIA NIH HHS/United States
- R01 AG059716/AG/NIA NIH HHS/United States
- R01 AG064233/AG/NIA NIH HHS/United States
- U01 AG052410/AG/NIA NIH HHS/United States
- P30 AG066509/AG/NIA NIH HHS/United States
- P30 AG066546/AG/NIA NIH HHS/United States
- R01 AG022018/AG/NIA NIH HHS/United States
- P30 AG072977/AG/NIA NIH HHS/United States
- P30 AG062677/AG/NIA NIH HHS/United States
- R01 AG027944/AG/NIA NIH HHS/United States
- UF1 NS100599/NS/NINDS NIH HHS/United States
- P30 AG072958/AG/NIA NIH HHS/United States
- P30 AG062715/AG/NIA NIH HHS/United States
- P30 AG066506/AG/NIA NIH HHS/United States
- P30 AG066468/AG/NIA NIH HHS/United States
- P30 AG072976/AG/NIA NIH HHS/United States
- P30 AG072947/AG/NIA NIH HHS/United States
- K24 AG046373/AG/NIA NIH HHS/United States
- P30 AG072931/AG/NIA NIH HHS/United States
- P30 AG066514/AG/NIA NIH HHS/United States
- P30 AG072959/AG/NIA NIH HHS/United States
- U19 AG066567/AG/NIA NIH HHS/United States
- P30 AG072979/AG/NIA NIH HHS/United States
- R01 AG015819/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Miscellaneous